Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Capital Expenditures (2018 - 2025)

TransMedics (TMDX) has 8 years of Capital Expenditures data on record, last reported at -$42.0 million in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 63.2% year-over-year to -$42.0 million; the TTM value through Dec 2025 reached $1.8 million, down 14.99%, while the annual FY2025 figure was $1.8 million, 14.99% down from the prior year.
  • Capital Expenditures reached -$42.0 million in Q4 2025 per TMDX's latest filing, down from $42.5 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $150.1 million in Q4 2023 and bottomed at -$114.1 million in Q4 2024.
  • Average Capital Expenditures over 5 years is $8.0 million, with a median of $167000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: surged 158800.0% in 2021, then tumbled 104080.49% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $3.2 million in 2021, then plummeted by 385.75% to -$9.1 million in 2022, then surged by 1753.15% to $150.1 million in 2023, then crashed by 175.99% to -$114.1 million in 2024, then soared by 63.2% to -$42.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$42.0 million in Q4 2025, $42.5 million in Q3 2025, and -$25.8 million in Q2 2025.